» Articles » PMID: 39896318

Exploration of Innovative Drug Repurposing Strategies for Combating Human Protozoan Diseases: Advances, Challenges, and Opportunities

Overview
Journal J Pharm Anal
Date 2025 Feb 3
PMID 39896318
Authors
Affiliations
Soon will be listed here.
Abstract

Protozoan infections (e.g., malaria, trypanosomiasis, and toxoplasmosis) pose a considerable global burden on public health and socioeconomic problems, leading to high rates of morbidity and mortality. Due to the limited arsenal of effective drugs for these diseases, which are associated with devastating side effects and escalating drug resistance, there is an urgent need for innovative antiprotozoal drugs. The emergence of drug repurposing offers a low-cost approach to discovering new therapies for protozoan diseases. In this review, we summarize recent advances in drug repurposing for various human protozoan diseases and explore cost-effective strategies to identify viable new treatments. We highlight the cross-applicability of repurposed drugs across diverse diseases and harness common chemical motifs to provide new insights into drug design, facilitating the discovery of new antiprotozoal drugs. Challenges and opportunities in the field are discussed, delineating novel directions for ongoing and future research.

References
1.
Pandey R, Nascimento M, Franco C, Bortoluci K, Silva M, Zingales B . Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi and . Antimicrob Agents Chemother. 2022; 66(11):e0028422. PMC: 9664849. DOI: 10.1128/aac.00284-22. View

2.
Costa R, Oliveira-da-Silva J, Reis T, Tavares G, Mendonca D, Freitas C . Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. Med Microbiol Immunol. 2021; 210(2-3):133-147. PMC: 8053370. DOI: 10.1007/s00430-021-00707-4. View

3.
Antinarelli L, Midlej V, da Silva E, Ferraz Coelho E, David da Silva A, Coimbra E . Exploring the repositioning of the amodiaquine as potential drug against visceral leishmaniasis: The in vitro effect against Leishmania infantum is associated with multiple mechanisms, involving mitochondria dysfunction, oxidative stress and loss of.... Chem Biol Interact. 2023; 371:110333. DOI: 10.1016/j.cbi.2022.110333. View

4.
Freitas C, Lage D, Oliveira-da-Silva J, Costa R, Mendonca D, Martins V . In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis. Parasite. 2021; 28:38. PMC: 8045677. DOI: 10.1051/parasite/2021036. View

5.
Borges B, Bueno G, Tomiotto-Pellissier F, Figueiredo F, Medeiros L . anti- activity of triclabendazole and its synergic effect with amphotericin B. Front Cell Infect Microbiol. 2023; 12:1044665. PMC: 9868945. DOI: 10.3389/fcimb.2022.1044665. View